Measuring Excipient-Market Growth - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Measuring Excipient-Market Growth
Moderate growth is projected for the global excipients market. Excipient producers target blends and new grades for improving functionality and performance.


Pharmaceutical Technology



PHOTO: STOCKBYTE/GETTY IMAGES
The global market for excipients is projected to grow at a stable rate for the next several years. New blends and grades of existing excipients are providing innovative ways to enhance multifunctionality and performance.

Market growth and segments


Patricia Van Arnum
The global market for excipients was $3.5 billion in 2006, according to BCC Research (1). The market is expected to increase at a compound annual growth rate (CAGR) of 3.8% through 2011 and reach $4.3 billion (see Table I). The global excipients market is broken down into three major segments: organic chemicals, inorganic chemicals, and United States Pharmacopeia (USP) water.

Organic chemicals. Carbohydrates represent the largest share of global organic excipients on a value basis, followed by petrochemicals, oleochemicals, and proteins. Carbohydrates account for 39%, or $1.2 billion, of the global organic excipient market based on 2006 data. Petrochemicals account for 30.3%, or $941 million, and oleochemicals 28.3%, or $880 million. Proteins represent a small percentage, only 2.2%, or $68 million, according to BCC Research (1).


Table I: The global excipient chemicals market (1).
Carbohydrates are the leading organic excipients because of their filling and taste-masking properties, according to BCC. Cellulosics hold the top spot in the carbohydrates segment on a value basis. Sugars comprise the bulk of the market volume for carbohydrates. Micronized cellulose phthalate and hydroxylpropyl cellulose compositions that have been converted to gels for transmucosal delivery systems are driving growth for cellulosics. BCC projects increased demand for compendial sugars for biopharmaceuticals and growth for artificial sweeteners, particularly in thin-film strips (1).

Glycols and povidones are the leading petrochemical-based excipients. "The trend in glycols is toward more refined grades that can increase stability of active pharmaceutical ingredients (APIs) by as much as threefold," reports BCC. "Also, the emergence of very small tablets with rapid bioavailability is helping to boost usage of povidones." For oleochemicals, demand is oriented toward topical products and shows relatively flat growth (1).

Inorganic chemicals . Inorganic chemicals used as pharmaceutical excipients include calcium salts, halites, metal oxides, and silicates. Calcium salts hold 73.2%, or $266 million, of the global inorganic excipients market, according to BCC. The firm points to several key developments for calcium salts:

  • The expiration of Rhodia's (Paris) patent for anhydrous technology, which could open the market to other products
  • The morphing of calcium phosphate from an excipient to a value-added product in a drug-delivery system
  • The development of a slow-release full-protection vaccine embedded into injectable microspheres made from dissolvable calcium-phosphate crystals; the microspheres surround nanoparticles containing the API.

Halites and metal oxides each comprise 8.5%, or $31 million, of the global market for inorganic excipients. Demand for sodium chloride as an osmotic agent in injections and sustained-release tablets provides halites a CAGR greater than that of other inorganic excipients, according to BCC. The established use of titanium dioxide as a colorant is driving sales growth of metal oxides. Silicates account for 4.8%, or $17 million, of the global market for inorganic excipients. Small loading levels and the maturity of the glidant segment keep the market for silicates low. Other inorganic excipients account for 5%, or $18 million (1).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here